Tags

Type your tag names separated by a space and hit enter

Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study.
Clin Endocrinol (Oxf) 1992; 37(1):45-50CE

Abstract

OBJECTIVE

To study longitudinally the effect of the menopause and hormone replacement therapy on the new markers of bone resorption: urinary excretion of pyridinoline and deoxypyridinoline.

DESIGN AND PATIENTS

Urinary pyridinoline and deoxypyridinoline were measured every 3 months for 2-3 years in 15 healthy women aged 45-54 years. Nine remained premenopausal and six became post-menopausal during the study. Urinary pyridinoline and deoxypyridinoline were also measured before and after 3 months of either placebo or hormone replacement therapy in 65 post-menopausal women, aged 45-54 years, who were participating in a double-blind study.

MEASUREMENTS

Urinary pyridinoline and deoxypyridinoline were measured in fasting urine samples by spectrofluorometry after high performance liquid chromatography and corrected for creatinine excretion.

RESULTS

Urinary pyridinoline and deoxypyridinoline remained almost constant during the premenopausal period. Both started to increase 6 months after the last menstrual bleeding and the mean post-menopausal values were 30-50% higher than the premenopausal values in the same subjects (values in nmol/mmol creatinine given as mean +/- SEM: urinary pyridinoline (premenopausal) = 29 +/- 2 vs urinary pyridinoline (post-menopausal) = 38 +/- 6, P < 0.05; urinary deoxypyridinoline (premenopausal) = 8 +/- 1 vs urinary deoxypyridinoline (post-menopausal) = 12 +/- 1, P < 0.05). Three months of post-menopausal hormone replacement therapy decreased (P < 0.001) both to premenopausal levels.

CONCLUSION

Urinary pyridinoline and deoxypyridinoline, new markers of bone resorption, remain fairly constant in the years before the menopause and start to increase about 6 months after the last menstrual bleeding. This increase is reversed by hormone replacement therapy.

Authors+Show Affiliations

Department of Clinical Chemistry, Glostrup Hospital, University of Copenhagen, Denmark.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

1424192

Citation

Hassager, C, et al. "Effect of Menopause and Hormone Replacement Therapy On Urinary Excretion of Pyridinium Cross-links: a Longitudinal and Cross-sectional Study." Clinical Endocrinology, vol. 37, no. 1, 1992, pp. 45-50.
Hassager C, Colwell A, Assiri AM, et al. Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study. Clin Endocrinol (Oxf). 1992;37(1):45-50.
Hassager, C., Colwell, A., Assiri, A. M., Eastell, R., Russell, R. G., & Christiansen, C. (1992). Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study. Clinical Endocrinology, 37(1), pp. 45-50.
Hassager C, et al. Effect of Menopause and Hormone Replacement Therapy On Urinary Excretion of Pyridinium Cross-links: a Longitudinal and Cross-sectional Study. Clin Endocrinol (Oxf). 1992;37(1):45-50. PubMed PMID: 1424192.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study. AU - Hassager,C, AU - Colwell,A, AU - Assiri,A M, AU - Eastell,R, AU - Russell,R G, AU - Christiansen,C, PY - 1992/7/1/pubmed PY - 1992/7/1/medline PY - 1992/7/1/entrez SP - 45 EP - 50 JF - Clinical endocrinology JO - Clin. Endocrinol. (Oxf) VL - 37 IS - 1 N2 - OBJECTIVE: To study longitudinally the effect of the menopause and hormone replacement therapy on the new markers of bone resorption: urinary excretion of pyridinoline and deoxypyridinoline. DESIGN AND PATIENTS: Urinary pyridinoline and deoxypyridinoline were measured every 3 months for 2-3 years in 15 healthy women aged 45-54 years. Nine remained premenopausal and six became post-menopausal during the study. Urinary pyridinoline and deoxypyridinoline were also measured before and after 3 months of either placebo or hormone replacement therapy in 65 post-menopausal women, aged 45-54 years, who were participating in a double-blind study. MEASUREMENTS: Urinary pyridinoline and deoxypyridinoline were measured in fasting urine samples by spectrofluorometry after high performance liquid chromatography and corrected for creatinine excretion. RESULTS: Urinary pyridinoline and deoxypyridinoline remained almost constant during the premenopausal period. Both started to increase 6 months after the last menstrual bleeding and the mean post-menopausal values were 30-50% higher than the premenopausal values in the same subjects (values in nmol/mmol creatinine given as mean +/- SEM: urinary pyridinoline (premenopausal) = 29 +/- 2 vs urinary pyridinoline (post-menopausal) = 38 +/- 6, P < 0.05; urinary deoxypyridinoline (premenopausal) = 8 +/- 1 vs urinary deoxypyridinoline (post-menopausal) = 12 +/- 1, P < 0.05). Three months of post-menopausal hormone replacement therapy decreased (P < 0.001) both to premenopausal levels. CONCLUSION: Urinary pyridinoline and deoxypyridinoline, new markers of bone resorption, remain fairly constant in the years before the menopause and start to increase about 6 months after the last menstrual bleeding. This increase is reversed by hormone replacement therapy. SN - 0300-0664 UR - https://www.unboundmedicine.com/medline/citation/1424192/Effect_of_menopause_and_hormone_replacement_therapy_on_urinary_excretion_of_pyridinium_cross_links:_a_longitudinal_and_cross_sectional_study_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=0300-0664&amp;date=1992&amp;volume=37&amp;issue=1&amp;spage=45 DB - PRIME DP - Unbound Medicine ER -